14 Result(s)

Article

Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT

More than 90% of gastrointestinal stromal tumors (GISTs) express the receptor tyrosine kinase KIT, and activating mutations of the KIT gene are detectable in the vast majority of these tumors. Imatinib mesylat...

Sebastian Bauer, Christopher L. Corless… in Cancer Chemotherapy and Pharmacology (2003)

Article

c-CBL is not required for leukemia induction by Bcr-Abl in mice

Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are require...

Daniela M Dinulescu, Lisa J Wood, Lei Shen, Marc Loriaux, Christopher L Corless… in Oncogene (2003)

Chapter

Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas

Michael C. Heinrich MD… in Targeting Treatment of Soft Tissue Sarcomas (2004)

Article

Gastrointestinal stromal tumors (GISTs) with KIT and PDGFRA mutations have distinct gene expression profiles

Most GISTs require oncogenic activation of the KIT or PDGFRA receptor tyrosine kinase proteins, and the genomic mechanisms of oncogene activation are heterogeneous. Notably, the kinase mutation type correlates wi...

Subbaya Subramanian, Robert B West, Christopher L Corless, Wenbin Ou… in Oncogene (2004)

Article

Does tumor mutational status correlate with clinical response to imatinib?

Michael C Heinrich, Christopher L Corless in Nature Clinical Practice Oncology (2006)

Article

Phosphatidylinositol-3-kinase and AKT1 mutations occur early in breast carcinoma

Mutationally activated protein kinases are appealing therapeutic targets in breast carcinoma. Mutations in phosphatidylinositol-3-kinase (PI3KCA) have been described in 8–40% of invasive breast carcinomas, and AK...

Jennifer Dunlap, Claudia Le, Arielle Shukla… in Breast Cancer Research and Treatment (2010)

Article

Absence of BRAF, NRAS, KRAS, HRAS Mutations, and RET/PTC Gene Rearrangements Distinguishes Dominant Nodules in Hashimoto Thyroiditis from Papillary Thyroid Carcinomas

Dominant nodules within Hashimoto thyroiditis (HT) may present with unique morphological features that overlap with but are not diagnostic of papillary thyroid carcinoma (PTC). Activating BRAF point mutations, RA...

Peter M. Sadow, Michael C. Heinrich, Christopher L. Corless… in Endocrine Pathology (2010)

Chapter

Practical Gastrointestinal Oncology Correlative Science

Gastrointestinal (GI) cancers, like other human malignancies, are characterized by the accumulation of a variety of genetic alterations, including mutations that lead to inactivation of tumor suppressor genes ...

Kay Washington, Christopher L. Corless in Gastrointestinal Oncology (2011)

Article

Novel Biomarker Candidates to Predict Hepatic Fibrosis in Hepatitis C Identified by Serum Proteomics

Liver biopsy remains the gold standard to assess hepatic fibrosis. It is desirable to predict hepatic fibrosis without the need for invasive liver biopsy. Proteomic techniques allow unbiased assessment of prot...

Libang Yang, Kyle D. Rudser, LeeAnn Higgins… in Digestive Diseases and Sciences (2011)

Article

Colorectal Cancer-Associated Spontaneous Tumor Lysis Syndrome: a Case Report and Review of the Current Literature

Matthew R. Kearney, Emerson Y. Chen, Peter Stenzel… in Journal of Gastrointestinal Cancer (2019)